Advances in leishmaniasis

[1]  S. Agrawal,et al.  Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. , 2005, The American journal of tropical medicine and hygiene.

[2]  F. Modabber,et al.  Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[3]  Daniel Nilsson,et al.  Comparative Genomics of Trypanosomatid Parasitic Protozoa , 2005, Science.

[4]  Heather J Munden,et al.  The Genome of the Kinetoplastid Parasite, Leishmania major , 2005, Science.

[5]  A. Khamesipour,et al.  Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. , 2005, Vaccine.

[6]  G. Matlashewski,et al.  Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  R. Coler,et al.  Second-generation vaccines against leishmaniasis. , 2005, Trends in parasitology.

[8]  R. Haque,et al.  Risk Factors for Kala-Azar in Bangladesh , 2005, Emerging infectious diseases.

[9]  J. Kolaczinski,et al.  Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  J. Kolaczinski,et al.  Social Impact of Leishmaniasis, Afghanistan , 2005, Emerging infectious diseases.

[11]  A. Barral,et al.  Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis. , 2005, Acta tropica.

[12]  A. Magill.  Cutaneous leishmaniasis in the returning traveler. , 2005, Infectious disease clinics of North America.

[13]  J. Berman,et al.  Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. , 2005, The American journal of tropical medicine and hygiene.

[14]  M. Gramiccia,et al.  Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature. , 2005, The Journal of antimicrobial chemotherapy.

[15]  A. Khamesipour,et al.  A randomized, double‐blind, placebo‐controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[16]  G. Wortmann,et al.  Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Spinelli,et al.  Dendritic cells in Leishmania infection. , 2004, Microbes and infection.

[18]  C. Corbett,et al.  Subclinical form of the American visceral leishmaniasis. , 2004, Memorias do Instituto Oswaldo Cruz.

[19]  P. Couppié,et al.  Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)‐infected patients and non‐HIV‐infected patients in French Guiana , 2004 .

[20]  E. Carvalho,et al.  Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. , 2004, The Journal of infectious diseases.

[21]  J. Soto,et al.  Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. , 2004, The American journal of tropical medicine and hygiene.

[22]  J. Wise.  Drive to produce more long-lasting insecticidal mosquito nets for malaria. , 2004, Bulletin of the World Health Organization.

[23]  P. Kaye,et al.  Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. , 2004, Trends in parasitology.

[24]  É. Rosenthal,et al.  Convenience of Serum for Visceral Leishmaniasis Diagnosis by PCR , 2004, Journal of Clinical Microbiology.

[25]  T. Poll,et al.  Elevated plasma levels of interferon (IFN)-γ, IFN-γ inducing cytokines, and IFN-γ inducible CXC chemokines in visceral leishmaniasis , 2004 .

[26]  S. Lawn,et al.  Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America , 2004, BMJ : British Medical Journal.

[27]  B. Beutler,et al.  The interface between innate and adaptive immunity , 2004, Nature Immunology.

[28]  A. Mergani,et al.  Evaluation of the direct agglutination test based on freeze‐dried Leishmania donovani promastigotes for the serodiagnosis of visceral leishmaniasis in Sudanese patients , 2004, Tropical medicine & international health : TM & IH.

[29]  Mark C Udey,et al.  Requirements for Th1-dependent immunity against infection with Leishmania major. , 2004, Microbes and infection.

[30]  C. Klersy,et al.  Diagnosis of visceral leishmaniasis: the sensitivities and specificities of traditional methods and a nested PCR assay , 2004, Annals of tropical medicine and parasitology.

[31]  D. Sacks,et al.  Re‐examination of the immunosuppressive mechanisms mediating non‐cure of Leishmania infection in mice , 2004, Immunological reviews.

[32]  D. Kaslow,et al.  A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[33]  D. Mcmahon-Pratt,et al.  Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? , 2004, Immunological reviews.

[34]  A. Khamesipour,et al.  Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. , 2004, Vaccine.

[35]  Z. Şimşek,et al.  The psychological impact of cutaneous leishmaniasis , 2004, Clinical and experimental dermatology.

[36]  J. M. Requena,et al.  Recent advances in vaccines for leishmaniasis , 2004, Expert opinion on biological therapy.

[37]  P. Desjeux.  Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[38]  E. Moreira,et al.  Assessment of an optimized dog-culling program in the dynamics of canine Leishmania transmission. , 2004, Veterinary parasitology.

[39]  A. Allahverdiyev,et al.  CLINICAL FEATURES, EPIDEMIOLOGY, AND EFFICACY AND SAFETY OF INTRALESIONAL ANTIMONY TREATMENT OF CUTANEOUS LEISHMANIASIS: RECENT EXPERIENCE IN TURKEY , 2004, The Journal of parasitology.

[40]  M. Ferguson,et al.  Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG , 2004, Nature.

[41]  S. Antinori,et al.  A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. , 2004, The Journal of antimicrobial chemotherapy.

[42]  M. Gramiccia,et al.  [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients]. , 2004, Parassitologia.

[43]  J. Blackwell,et al.  Genetics and visceral leishmaniasis in the Sudan: seeking a link. , 2004, Trends in parasitology.

[44]  J. Soto,et al.  Miltefosine for new world cutaneous leishmaniasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  M. Wilson,et al.  Novel Program of Macrophage Gene Expression Induced by Phagocytosis of Leishmania chagasi , 2004, Infection and Immunity.

[46]  D. Campbell-Lendrum,et al.  Predicting Geographic Variation in Cutaneous Leishmaniasis, Colombia , 2004, Emerging infectious diseases.

[47]  H. Murray.  Progress in the treatment of a neglected infectious disease: visceral leishmaniasis , 2004, Expert review of anti-infective therapy.

[48]  E. Rodrigues,et al.  Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? , 2004, The Journal of infectious diseases.

[49]  W. Cevallos,et al.  Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. , 2004, Vaccine.

[50]  G K Smyth,et al.  Leishmaniasis host response loci (lmr1–3) modify disease severity through a Th1/Th2-independent pathway , 2004, Genes and Immunity.

[51]  C. Davies,et al.  Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  M. Fernández-Guerrero,et al.  Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. , 2004, Acta tropica.

[53]  C. P. Thakur,et al.  A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis , 2004, Annals of tropical medicine and parasitology.

[54]  M. Ulrich,et al.  Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report. , 2004, Memorias do Instituto Oswaldo Cruz.

[55]  B. Beutler.  Innate immunity: an overview. , 2004, Molecular immunology.

[56]  S. Sundar,et al.  Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  C. Riera,et al.  Detection of Leishmania infantum cryptic infection in asymptomatic blood donors living in an endemic area (Eivissa, Balearic Islands, Spain) by different diagnostic methods. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[58]  P. Desjeux,et al.  Treatment of cutaneous leishmaniasis among travellers. , 2004, The Journal of antimicrobial chemotherapy.

[59]  S. Sundar,et al.  Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  R. Locksley,et al.  Leishmania major LACK Antigen Is Required for Efficient Vertebrate Parasitization , 2003, The Journal of experimental medicine.

[61]  R. Haque,et al.  Visceral leishmaniasis: consequences of a neglected disease in a Bangladeshi community. , 2003, The American journal of tropical medicine and hygiene.

[62]  A. Barral,et al.  Clinical utility of polymerase chain reaction-based detection of Leishmania in the diagnosis of American cutaneous leishmaniasis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  A. Rabello,et al.  Leishmania/HIV co-infection in Brazil: an appraisal , 2003, Annals of tropical medicine and parasitology.

[64]  G. H. Coombs,et al.  Cysteine Protease B of Leishmania mexicana Inhibits Host Th1 Responses and Protective Immunity 1 , 2003, The Journal of Immunology.

[65]  F. Laguna.  Treatment of leishmaniasis in HIV-positive patients , 2003, Annals of tropical medicine and parasitology.

[66]  M. Cotarelo,et al.  Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  S. Sundar,et al.  Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  Anirban Ghosh,et al.  Comparison of the A2 Gene Locus in Leishmania donovani and Leishmania major and Its Control over Cutaneous Infection* , 2003, Journal of Biological Chemistry.

[69]  R. Davidson,et al.  Emergence or re-emergence of visceral leishmaniasis in areas of Somalia, north-eastern Kenya, and south-eastern Ethiopia in 2000-01. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[70]  Jean M. Long,et al.  Visceral leishmaniasis and HIV in Tigray, Ethiopia , 2003, Tropical medicine & international health : TM & IH.

[71]  M. Gramiccia,et al.  Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). , 2003, The Journal of antimicrobial chemotherapy.

[72]  L. Garraway,et al.  The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[73]  T. Lavabre‐Bertrand,et al.  Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure. , 2003, The Journal of infection.

[74]  L. Oskam,et al.  Value of diagnostic techniques for cutaneous leishmaniasis. , 2003, Journal of the American Academy of Dermatology.

[75]  A. Momeni,et al.  The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis , 2003, Annals of tropical medicine and parasitology.

[76]  R. Armijos,et al.  Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: how long does protection last? , 2003, Journal of Infectious Diseases.

[77]  A. Sadeghinia,et al.  Efficacy of permethrin‐impregnated uniforms in the prevention of cutaneous leishmaniasis in Iranian soldiers , 2003, Journal of clinical pharmacy and therapeutics.

[78]  F. Chappuis,et al.  Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[79]  J. Navarro,et al.  Localized Mucosal Leishmaniasis due to Leishmania (Leishmania) infantum: Clinical and Microbiologic Findings in 31 Patients , 2003, Medicine.

[80]  S. Bertholet,et al.  Leishmania donovani-Induced Expression of Suppressor of Cytokine Signaling 3 in Human Macrophages: a Novel Mechanism for Intracellular Parasite Suppression of Activation , 2003, Infection and Immunity.

[81]  F. Vega‐López.  Diagnosis of cutaneous leishmaniasis , 2003, Current opinion in infectious diseases.

[82]  V. Schall,et al.  Evaluation of informative materials on leishmaniasis distributed in Brazil: criteria and basis for the production and improvement of health education materials. , 2003, Cadernos de saude publica.

[83]  G. Daikos,et al.  Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[84]  S. Schultz-Cherry,et al.  Activation of TGF-β by Leishmania chagasi: Importance for Parasite Survival in Macrophages 1 , 2003, The Journal of Immunology.

[85]  M. Rowland,et al.  The prolonged epidemic of anthroponotic cutaneous leishmaniasis in Kabul, Afghanistan: 'bringing down the neighbourhood'. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[86]  S. Croft,et al.  Leishmaniasis: new approaches to disease control , 2003, BMJ : British Medical Journal.

[87]  S. Sundar,et al.  Diagnosis and treatment of Indian visceral leishmaniasis. , 2003, The Journal of the Association of Physicians of India.

[88]  R. Davidson,et al.  Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala‐azar in Sudan , 2003, Tropical medicine & international health : TM & IH.

[89]  E. Zijlstra,et al.  Post-kala-azar dermal leishmaniasis. , 2003, The Lancet. Infectious diseases.

[90]  E. Carvalho,et al.  Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. , 2002, The Journal of infectious diseases.

[91]  P. Machado,et al.  Up-Regulation of Th1-Type Responses in Mucosal Leishmaniasis Patients , 2002, Infection and Immunity.

[92]  R. A. Thompson,et al.  Climatic and demographic determinants of American visceral leishmaniasis in northeastern Brazil using remote sensing technology for environmental categorization of rain and region influences on leishmaniasis. , 2002, The American journal of tropical medicine and hygiene.

[93]  E. Pugh,et al.  Association between the Tumor Necrosis Factor Locus and the Clinical Outcome of Leishmania chagasi Infection , 2002, Infection and Immunity.

[94]  Shyam Sundar,et al.  Oral miltefosine for Indian visceral leishmaniasis. , 2002, The New England journal of medicine.

[95]  J. C. Miranda,et al.  Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. , 2002, The Journal of infectious diseases.

[96]  C. Dye,et al.  Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. , 2002, The Journal of infectious diseases.

[97]  A. Sher,et al.  Evasion of innate immunity by parasitic protozoa , 2002, Nature Immunology.

[98]  D. Sacks,et al.  The immunology of susceptibility and resistance to Leishmania major in mice , 2002, Nature Reviews Immunology.

[99]  R. Coffman,et al.  Interleukin-10 (IL-10) in Experimental Visceral Leishmaniasis and IL-10 Receptor Blockade as Immunotherapy , 2002, Infection and Immunity.

[100]  A. Kroeger,et al.  Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial , 2002, BMJ : British Medical Journal.

[101]  E. Paraguai de Souza,et al.  Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). , 2002, Vaccine.

[102]  M. Rai,et al.  Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[103]  A S Mazloumi Gavgani,et al.  Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matchedcluster randomised trial , 2002, The Lancet.

[104]  D. Sacks,et al.  Leishmania Priming of Human Dendritic Cells for CD40 Ligand-Induced Interleukin-12p70 Secretion Is Strain and Species Dependent , 2002, Infection and Immunity.

[105]  Shyam Sundar,et al.  Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.

[106]  Gavin Yamey,et al.  The world's most neglected diseases , 2002, BMJ : British Medical Journal.

[107]  P. Machado,et al.  Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[108]  B. Clarissa,et al.  Epidemiologic and Immunologic Findings for the Subclinical Form of Leishmania braziliensis Infection , 2002 .

[109]  J. M. Rubio,et al.  Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. , 2002, The Journal of infectious diseases.

[110]  A. Walker,et al.  The Urban Spread of Visceral Leishmaniasis: Clues from Spatial Analysis , 2002, Epidemiology.

[111]  J. Alvar,et al.  Leishmania in discarded syringes from intravenous drug users , 2002, The Lancet.

[112]  J. Maguire,et al.  Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. , 2002, The New England journal of medicine.

[113]  W. McMaster,et al.  Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. , 2002, Molecular and biochemical parasitology.

[114]  S. Sundar,et al.  Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. , 2002, The American journal of tropical medicine and hygiene.

[115]  P. Launois,et al.  High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment. , 2001, The Journal of infectious diseases.

[116]  L. Gradoni,et al.  Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin‐impregnated dog collars in southern Italy , 2001, Medical and veterinary entomology.

[117]  Y. Belkaid,et al.  The Role of Interleukin (IL)-10 in the Persistence of Leishmania major in the Skin after Healing and the Therapeutic Potential of Anti–IL-10 Receptor Antibody for Sterile Cure , 2001, The Journal of experimental medicine.

[118]  M. V. Guerra,et al.  Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. , 2001, The American journal of tropical medicine and hygiene.

[119]  B. Arana,et al.  Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. , 2001, The American journal of tropical medicine and hygiene.

[120]  S. Sundar.  Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[121]  H. Murray.  Tissue granuloma structure‐function in experimental visceral leishmaniasis , 2001, International journal of experimental pathology.

[122]  R. Reithinger,et al.  Topical insecticide treatments to protect dogs from sand fly vectors of leishmaniasis. , 2001, Emerging infectious diseases.

[123]  T. Souto-Padrón,et al.  Occurrence of Leishmania donovani parasitemia in plasma of infected hamsters. , 2001, Acta tropica.

[124]  M. Rai,et al.  Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. , 2001, BMJ : British Medical Journal.

[125]  Á. Cruz,et al.  Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. , 2001, The American journal of tropical medicine and hygiene.

[126]  P. Melby,et al.  Leishmania donovani p36(LACK) DNA Vaccine Is Highly Immunogenic but Not Protective against Experimental Visceral Leishmaniasis , 2001, Infection and Immunity.

[127]  H. Murray.  Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis , 2001, Antimicrobial Agents and Chemotherapy.

[128]  P. Desjeux.  The increase in risk factors for leishmaniasis worldwide. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[129]  S. Pattanayak.  Kala-azar: a potentially eradicable disease as a public health challenge. , 2001, Indian journal of public health.

[130]  A. Elhassan,et al.  Leishmaniasis in Sudan. 3. Visceral leishmaniasis , 2001 .

[131]  D. Sacks,et al.  Leishmania–sand fly interactions controlling species‐specific vector competence , 2001, Cellular microbiology.

[132]  E. Handman.  Leishmaniasis: Current Status of Vaccine Development , 2001, Clinical Microbiology Reviews.

[133]  P. Launois,et al.  Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. , 2001, The Journal of infectious diseases.

[134]  G. Matlashewski,et al.  General Suppression of Macrophage Gene Expression During Leishmania donovani Infection1 , 2001, The Journal of Immunology.

[135]  L. Osorio,et al.  Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. , 2001, The American journal of tropical medicine and hygiene.

[136]  E. Bouza,et al.  Visceral Leishmaniasis in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients: A Comparative Study , 2001, Medicine.

[137]  J. Cosín,et al.  Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. , 2000, AIDS.

[138]  F. Modabber,et al.  Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan , 2000, The Lancet.

[139]  C. Davies,et al.  Spraying houses in the Peruvian Andes with lambda-cyhalothrin protects residents against cutaneous leishmaniasis. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[140]  C. Muskus,et al.  Diagnosis of Cutaneous Leishmaniasis in Colombia: the Sampling Site within Lesions Influences the Sensitivity of Parasitologic Diagnosis , 2000, Journal of Clinical Microbiology.

[141]  S. Sundar,et al.  Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  D. Campbell-Lendrum,et al.  The epidemiology and control of leishmaniasis in Andean countries. , 2000, Cadernos de saude publica.

[143]  J. Shaw,et al.  Competence of the human host as a reservoir for Leishmania chagasi. , 2000, The Journal of infectious diseases.

[144]  A. Joshi,et al.  Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. , 2000, The American journal of tropical medicine and hygiene.

[145]  L. Oskam,et al.  Leishmaniasis in the Sudan: a literature review with emphasis on clinical aspects , 2000, Tropical medicine & international health : TM & IH.

[146]  John T. Chang,et al.  Requirements for the Maintenance of Th1 Immunity In Vivo Following DNA Vaccination: A Potential Immunoregulatory Role for CD8+ T Cells , 2000, The Journal of Immunology.

[147]  Y. Belkaid,et al.  A Natural Model of Leishmania major Infection Reveals a Prolonged “Silent” Phase of Parasite Amplification in the Skin Before the Onset of Lesion Formation and Immunity , 2000, The Journal of Immunology.

[148]  M. Rowland,et al.  A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[149]  K. Ritmeijer,et al.  A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan , 2000, Tropical medicine & international health : TM & IH.

[150]  A. Kharazmi,et al.  Comparison of the Immune Profile of Nonhealing Cutaneous Leishmaniasis Patients with Those with Active Lesions and Those Who Have Recovered from Infection , 2000, Infection and Immunity.

[151]  M. Ray,et al.  Inhibition of Interferon-γ Signaling by Leishmania donovani , 2000 .

[152]  C. Davies,et al.  Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran , 1999, Parasitology.

[153]  J. Quaranta,et al.  Occurrence of Leishmania infantum Parasitemia in Asymptomatic Blood Donors Living in an Area of Endemicity in Southern France , 1999, Journal of Clinical Microbiology.

[154]  A. Khamesipour,et al.  A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. , 1999, Vaccine.

[155]  M. Grogl,et al.  Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent U.S. military experience. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[156]  K. Dellagi,et al.  Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. , 1998, The Journal of infectious diseases.

[157]  A. Khamesipour,et al.  Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran , 1998, The Lancet.

[158]  D. Lockwood,et al.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. , 1998, BMJ.

[159]  S. Sundar,et al.  Splenic cytokine responses in Indian kala-azar before and after treatment. , 1998, The Journal of infectious diseases.

[160]  T. Theander,et al.  High levels of plasma IL‐10 and expression of IL‐10 by keratinocytes during visceral leishmaniasis predict subsequent development of post‐kala‐azar dermal leishmaniasis , 1998, Clinical and experimental immunology.

[161]  A. Alkhawajah,et al.  Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. , 1997, Annals of tropical medicine and parasitology.

[162]  S Sharma,et al.  Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. , 1997, The American journal of tropical medicine and hygiene.

[163]  J. Berman,et al.  Inefficacy of Allopurinol as Monotherapy for Colombian Cutaneous Leishmaniasis , 1997, Annals of Internal Medicine.

[164]  Y. Dowlati.  Cutaneous leishmaniasis: clinical aspect. , 1996, Clinics in dermatology.

[165]  N. Saravia,et al.  Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis. , 1996, Clinics in dermatology.

[166]  P. Olliaro,et al.  A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. , 1995, The American journal of tropical medicine and hygiene.

[167]  J. Blackwell,et al.  Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis , 1995, The Journal of experimental medicine.

[168]  E. Carvalho,et al.  Lymphadenopathy as the first sign of human cutaneous infection by Leishmania braziliensis. , 1995, The American journal of tropical medicine and hygiene.

[169]  P. Olliaro,et al.  A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. , 1995, The American journal of tropical medicine and hygiene.

[170]  T. Rosen,et al.  Treatment of cutaneous leishmaniasis. , 1994, Journal of the American Academy of Dermatology.

[171]  B. Arana,et al.  Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[172]  M. Ulrich,et al.  The clinical and immunological spectrum of American cutaneous leishmaniasis. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[173]  J. Berman,et al.  Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[174]  B. Arana,et al.  The natural history of cutaneous leishmaniasis in Guatemala. , 1992, The Journal of infectious diseases.

[175]  R. Badaró,et al.  Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. , 1992, The Journal of infectious diseases.

[176]  B. Arana,et al.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. , 1992, The Journal of infectious diseases.

[177]  P. Bongrand,et al.  Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: differences in gamma interferon production between this population and visceral leishmaniasis patients , 1991, Parasite immunology.

[178]  J. Berman,et al.  Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. , 1990, Annals of internal medicine.

[179]  J. Berman,et al.  Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. , 1990, The American journal of medicine.

[180]  R. Badaró,et al.  Malnutrition as a risk factor for severe visceral leishmaniasis. , 1987, The Journal of infectious diseases.

[181]  S. Reed,et al.  New perspectives on a subclinical form of visceral leishmaniasis. , 1986, The Journal of infectious diseases.

[182]  A. Vlug,et al.  Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class- and subclass-specific reagents. , 1986, Clinical and experimental immunology.

[183]  J. El-on,et al.  Topical treatment of cutaneous leishmaniasis. , 1985, British medical journal.

[184]  Sebastião A. Prado Sampaio,et al.  TREATMENT OF MUCOCUTANEOUS (AMERICAN) LEISHMANIASIS WITH AMPHOTERICIN B: REPORT OF 7O CASES , 1971, International journal of dermatology.

[185]  W. Caiaffa,et al.  Risk factors for mucosal manifestation of American cutaneous leishmaniasis. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[186]  G. Romero,et al.  Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. , 2005, Acta tropica.

[187]  M. Itoh,et al.  Direct agglutination test with urine samples for the diagnosis of visceral leishmaniasis. , 2004, The American journal of tropical medicine and hygiene.

[188]  Patrick Van der Stuyft,et al.  A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. , 2004, The American journal of tropical medicine and hygiene.

[189]  T. van der Poll,et al.  Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. , 2004, The American journal of tropical medicine and hygiene.

[190]  C. Corbett,et al.  Serum cytokine profile in the subclinical form of visceral leishmaniasis. , 2004, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[191]  P. Martínez Sánchez,et al.  Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[192]  J. Macías,et al.  Leishmania infantum (Protozoa, kinetoplastida): transmission from infected patients to experimental animal under conditions that simulate needle-sharing. , 2002, Experimental parasitology.

[193]  F. Handjani,et al.  Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. , 2001, The Journal of dermatological treatment.

[194]  M. Ray,et al.  Inhibition of interferon-gamma signaling by Leishmania donovani. , 2000, The Journal of infectious diseases.

[195]  J. Soto,et al.  Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[196]  S. R. Costa,et al.  Asymptomatic Leishmania chagasi infection in relatives and neighbors of patients with visceral leishmaniasis. , 1997, Memorias do Instituto Oswaldo Cruz.

[197]  F. Cox,et al.  Old World leishmaniasis. , 1996 .

[198]  T. K. Jha.  Evaluation of diamidine compound (pentamidine isethionate) in the treatment resistant cases of kala-azar occurring in North Bihar, India. , 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[199]  A. Bryceson.  Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. , 1969, Transactions of the Royal Society of Tropical Medicine and Hygiene.